Lv2
170 积分 2022-08-12 加入
Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement
6天前
已完结
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
25天前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
25天前
已完结
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
1个月前
已完结
PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?
2个月前
已完结
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
2个月前
已完结
ESMO-Magnitude of Clinical Benefit Scale version 1.1
2个月前
已完结
EIF3B Promotes KRAS Gene Mutation‐Driven Colon Adenocarcinoma Progression Through the TBK1 and PI3K/AKT Signaling Pathways
3个月前
已完结
Diagnostic yields and safety of thoracoscopic cryobiopsies in Japan: A single-center retrospective observational study
3个月前
已完结
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population
3个月前
已完结
皖公网安备34019202002308
